2011
Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
Olsen EA, Whittaker S, Kim YH, Duvic M, Prince HM, Lessin SR, Wood GS, Willemze R, Demierre MF, Pimpinelli N, Bernengo MG, Ortiz-Romero PL, Bagot M, Estrach T, Guitart J, Knobler R, Sanches JA, Iwatsuki K, Sugaya M, Dummer R, Pittelkow M, Hoppe R, Parker S, Geskin L, Pinter-Brown L, Girardi M, Burg G, Ranki A, Vermeer M, Horwitz S, Heald P, Rosen S, Cerroni L, Dreno B, Vonderheid EC. Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. Journal Of Clinical Oncology 2011, 29: 2598-2607. PMID: 21576639, PMCID: PMC3422534, DOI: 10.1200/jco.2010.32.0630.Peer-Reviewed Original ResearchConceptsMF/Sézary syndromeSézary syndromeMycosis fungoidesClinical trialsEnd pointResponse criteriaUnited States Cutaneous Lymphoma ConsortiumCutaneous T-cell lymphomaCutaneous Lymphoma Task ForceInvestigator-initiated clinical trialsPotential disease manifestationsClinical end pointsEarly mycosis fungoidesT-cell lymphomaUniform stagingCutaneous lymphomasLymph nodesTreatment of cancerHodgkin's lymphomaDisease manifestationsConsensus statementConsensus recommendationsVisceral organsEuropean OrganizationLymphoma
2005
Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance
Oppenheim DE, Roberts SJ, Clarke SL, Filler R, Lewis JM, Tigelaar RE, Girardi M, Hayday AC. Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nature Immunology 2005, 6: 928-937. PMID: 16116470, DOI: 10.1038/ni1239.Peer-Reviewed Original ResearchMeSH Keywords9,10-Dimethyl-1,2-benzanthraceneAnimalsCarcinomaCell Line, TumorDisease SusceptibilityDown-RegulationFemaleImmunologic SurveillanceKiller Cells, NaturalLigandsMaleMembrane ProteinsMiceMice, Inbred C57BLMice, KnockoutMice, TransgenicNK Cell Lectin-Like Receptor Subfamily KPapillomaReceptors, ImmunologicReceptors, Natural Killer CellSkin NeoplasmsTetradecanoylphorbol AcetateT-LymphocytesTumor BurdenConceptsNKG2D downregulationNK cell-mediated cytotoxicityNatural killer cellsCell-mediated cytotoxicityInnate immune activationT cell defectsNKG2D engagementNatural cytotoxicityKiller cellsImmune activationReceptor NKG2DTumor immunosurveillanceCutaneous carcinogenesisTumor surveillanceT cellsReversible defectsRAE-1Normal epitheliumLigand expressionTumor resistanceCell defectsSustained expressionNKG2DImmunosurveillanceDownregulation